Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT: Belatacept in Kidney Transplantation
NCT00256750Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2005
- Primary completion
- Jun 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 21
01
Overview
A Phase 3 trial of belatacept in kidney transplant rejection, sponsored by Bristol Myers Squibb. Started Mar 2005; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00256750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256750.